Boehringer Ingelheim produces its own green energy
July 08, 2024 13:15 ET
|
Boehringer Ingelheim
German Vice Chancellor and Federal Minister of Economics Robert Habeck inaugurates new biomass power plantIngelheim site can cover 95% of its energy needs from renewable sourcesNew power plant helps...
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
June 07, 2024 04:30 ET
|
Boehringer Ingelheim
News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH)...
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
May 28, 2024 07:00 ET
|
Boehringer Ingelheim
International analysis of mental health provision in eight G20 countries reveals stigma, a shortage of mental health professionals and inconsistent availability and quality of care are creating...
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia
May 06, 2024 05:00 ET
|
Boehringer Ingelheim
Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic...
Less than half of veterinary professionals feel their profession is appreciated
April 25, 2024 03:00 ET
|
Boehringer Ingelheim
World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated. Veterinary associations and...
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
April 16, 2024 04:35 ET
|
Boehringer Ingelheim
Human Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCE® and OFEV®Animal Health sales up 6.9 %* to EUR 4.7 bn, fueled by new product launchesR&D expenditures increase by 14.2% to EUR 5.8...
SPEVIGO® approved for expanded indications in China and the US
March 19, 2024 07:00 ET
|
Boehringer Ingelheim
Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue1,2,3,4In China,...
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
February 26, 2024 02:05 ET
|
Boehringer Ingelheim
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of...
New collaboration between Boehringer Ingelheim and Sleip leverages AI-technology to help detect lameness in horses
February 19, 2024 04:00 ET
|
Boehringer Ingelheim
The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone. A new global commercial partnership between Boehringer Ingelheim...
Boehringer expands production site in Greece for new medicine
January 11, 2024 10:15 ET
|
Boehringer Ingelheim
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece. With an investment of EUR 120 million, the...